Publicação

Endocan as a marker of endotheliitis in COVID-19 patients

Ver documento

Detalhes bibliográficos
Resumo:BACKGROUND AND AIMS: Endocan has been scarcely explored in COVID-19, especially regarding its modulation by veno-venous extracorporeal membrane oxygenation (VV-ECMO), hypertension or previous renin-angiotensin-aldosterone system (RAAS) inhibitors treatment. We compared endocan and other endotheliitis markers in hospitalized COVID-19 patients and assessed their modulation by VV-ECMO, hypertension and previous RAAS inhibitors treatment. MATERIAL AND METHODS: Serum endocan, intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and E-selectin were measured in "severe" (n = 27), "critically ill" (n = 17) and "critically ill on VV-ECMO" (n = 17) COVID-19 patients at admission, days 3-4, 5-8 and weekly thereafter, and in controls (n = 23) at a single time point. RESULTS: Admission endocan and VCAM-1 were increased in all patients, but "critically ill on VV-ECMO" patients had higher endocan and E-Selectin. Endocan remained elevated throughout hospitalization in all groups. "Severe" and "critically ill" hypertensive patients or previously treated with RAAS inhibitors had higher endocan and/or VCAM-1, but in VV-ECMO patients the raised endocan values seemed unrelated with these factors. Among all COVID-19 hypertensive patients, those with previous RAAS inhibitors treatment had higher endocan. CONCLUSIONS: In our study, endocan stands out as the best marker of endotheliitis in hospitalized COVID-19 patients, being upregulated by VV-ECMO support, hypertension and previous RAAS inhibitor treatment.
Autores principais:Reina-Couto, Marta
Outros Autores:Alves, David; Silva-Pereira, Carolina; Pereira-Terra, Patrícia; Martins, Sandra; Bessa, João; Teixeira-Santos, Luísa; Pinho, Dora; Morato, Manuela; Dias, Cláudia Camila; Sarmento, António; Tavares, Margarida; Guimarães, João T.; Roncon-Albuquerque, Roberto; Paiva, José Artur; Albino-Teixeira, António; Sousa, Teresa
Assunto:COVID-19 Endocan Endotheliitis Hypertension RAAS inhibitors VV-ECMO Immunology Pharmacology
Ano:2025
País:Portugal
Tipo de documento:artigo
Tipo de acesso:acesso aberto
Instituição associada:Universidade Nova de Lisboa
Idioma:inglês
Origem:Repositório Institucional da UNL

Registos relacionados

Registos relacionados